Systemic Inflammation Response Index is an Independent Prognostic Indicator for Patients with Renal Cell Carcinoma Undergoing Laparoscopic Nephrectomy: A Multi-Institutional Cohort Study

References

• SiegelRL, MillerKD, FuchsHE, JemalA. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.2165433433946
   PubMed Web of Science ®Google Scholar
• LjungbergB, BensalahK, CanfieldS, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–924. doi:10.1016/j.eururo.2015.01.00525616710
   PubMed Web of Science ®Google Scholar
• MargulisV, SagalowskyAI. Penile cancer: management of regional lymphatic drainage. Urol Clin North Am. 2010;37(3):411–419. doi:10.1016/j.ucl.2010.04.00920674696
   PubMed Web of Science ®Google Scholar
• ChenW, ZhengR, BaadePD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• TannirNM, PalSK, AtkinsMB. Second-line treatment landscape for renal cell carcinoma: a comprehensive review. Oncologist. 2018;23(5):540–555. doi:10.1634/theoncologist.2017-053429487224
   PubMed Web of Science ®Google Scholar
• MaoW, WangK, ZhangH, et al. Sarcopenia as a poor prognostic indicator for renal cell carcinoma patients undergoing nephrectomy in China: a multicenter study. Clin Transl Med. 2021;11(1):e270. doi:10.1002/ctm2.27033463055
   PubMed Web of Science ®Google Scholar
• YongC, StewartGD, FrezzaC. Oncometabolites in renal cancer. Nat Rev Nephrol. 2020;16(3):156–172. doi:10.1038/s41581-019-0210-z31636445
   PubMed Web of Science ®Google Scholar
• BianchiM, SunM, JeldresC, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2012;23(4):973–980. doi:10.1093/annonc/mdr36221890909
   PubMed Web of Science ®Google Scholar
• JiF, LiangY, FuSJ, et al. A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI). BMC Cancer. 2016;16:137. doi:10.1186/s12885-016-2189-126907597
   PubMed Web of Science ®Google Scholar
• DiakosCI, CharlesKA, McMillanDC, ClarkeSJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503. doi:10.1016/S1470-2045(14)70263-325281468
   PubMed Web of Science ®Google Scholar
• GuL, MaX, LiH, et al. Prognostic value of preoperative inflammatory response biomarkers in patients with sarcomatoid renal cell carcinoma and the establishment of a nomogram. Sci Rep. 2016;6:23846. doi:10.1038/srep2384627035802
   PubMed Web of Science ®Google Scholar
• DupreA, MalikHZ. Inflammation and cancer: what a surgical oncologist should know. Eur J Surg Oncol. 2018;44(5):566–570. doi:10.1016/j.ejso.2018.02.20929530345
   PubMed Web of Science ®Google Scholar
• DemirdalT, SenP. The significance of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and lymphocyte-monocyte ratio in predicting peripheral arterial disease, peripheral neuropathy, osteomyelitis and amputation in diabetic foot infection. Diabetes Res Clin Pract. 2018;144:118–125. doi:10.1016/j.diabres.2018.08.00930176260
   PubMed Web of Science ®Google Scholar
• MotzerRJ, BacikJ, SchwartzLH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22(3):454–463. doi:10.1200/JCO.2004.06.13214752067
   PubMed Web of Science ®Google Scholar
• McMillanDC. The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–540. doi:10.1016/j.ctrv.2012.08.00322995477
   PubMed Web of Science ®Google Scholar
• GuL, MaX, WangL, et al. Prognostic value of a systemic inflammatory response index in metastatic renal cell carcinoma and construction of a predictive model. Oncotarget. 2017;8(32):52094–52103. doi:10.18632/oncotarget.1062628881716
   PubMedGoogle Scholar
• FukudaH, TakagiT, KondoT, ShimizuS, TanabeK. Predictive value of inflammation-based prognostic scores in patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy. Oncotarget. 2018;9(18):14296–14305. doi:10.18632/oncotarget.2450729581844
   PubMedGoogle Scholar
• FicarraV, NovaraG, IafrateM, et al. Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3-4) renal cell carcinoma according to the cancer-related outcome. Eur Urol. 2007;51(3):722–9; discussion 9–31. doi:10.1016/j.eururo.2006.07.010
   Web of Science ®Google Scholar
• LamJS, BredaA, BelldegrunAS, FiglinRA. Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J Clin Oncol. 2006;24(35):5565–5575. doi:10.1200/JCO.2006.08.179417158542
   PubMed Web of Science ®Google Scholar
• WatsonJ, RoundA, HamiltonW. Raised inflammatory markers. BMJ. 2012;344:e454. doi:10.1136/bmj.e45422306478
   PubMed Web of Science ®Google Scholar
• MurrayPJ. Immune regulation by monocytes. Semin Immunol. 2018;35:12–18. doi:10.1016/j.smim.2017.12.00529290545
   PubMed Web of Science ®Google Scholar
• Garcia-FlorezLJ, Gomez-AlvarezG, FrunzaAM, Barneo-SerraL, Martinez-AlonsoC, Fresno-ForcelledoMF. Predictive markers of response to neoadjuvant therapy in rectal cancer. J Surg Res. 2015;194(1):120–126. doi:10.1016/j.jss.2014.10.00525481527
   PubMed Web of Science ®Google Scholar
• HusznoJ, KoloszaZ, Mrochem-KwarciakJ, RutkowskiT, SkladowskiK. The role of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and platelets in the prognosis of metastatic renal cell carcinoma. Oncology. 2019;97(1):7–17. doi:10.1159/00049894331048577
   PubMed Web of Science ®Google Scholar
• ChromP, StecR, BodnarL, SzczylikC. Incorporating neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in place of neutrophil count and platelet count improves prognostic accuracy of the international metastatic renal cell carcinoma database consortium model. Cancer Res Treat. 2018;50(1):103–110. doi:10.4143/crt.2017.03328253564
   PubMed Web of Science ®Google Scholar
• RuddleNH. Lymphatic vessels and tertiary lymphoid organs. J Clin Invest. 2014;124(3):953–959. doi:10.1172/JCI7161124590281
   PubMed Web of Science ®Google Scholar
• KauffmanEC, LiuH, SchwartzMJ, ScherrDS. Toll-like receptor 7 agonist therapy with imidazoquinoline enhances cancer cell death and increases lymphocytic infiltration and proinflammatory cytokine production in established tumors of a renal cell carcinoma mouse model. J Oncol. 2012;2012:103298. doi:10.1155/2012/10329822481916
   PubMedGoogle Scholar
• BauerJ, BeckerAJ, ElyamanW, et al. Innate and adaptive immunity in human epilepsies. Epilepsia. 2017;58(Suppl 3):57–68. doi:10.1111/epi.1378428675562
   PubMed Web of Science ®Google Scholar
• RaphaelI, NalawadeS, EagarTN, ForsthuberTG. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine. 2015;74(1):5–17. doi:10.1016/j.cyto.2014.09.01125458968
   PubMed Web of Science ®Google Scholar
• DonskovF, HoklandM, MarcussenN, Torp MadsenHH, von der MaaseH. Monocytes and neutrophils as ‘bad guys’ for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma–results from a randomised Phase II trial. Br J Cancer. 2006;94(2):218–226. doi:10.1038/sj.bjc.660293716434984
   PubMed Web of Science ®Google Scholar
• AllavenaP, SicaA, SolinasG, PortaC, MantovaniA. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 2008;66(1):1–9. doi:10.1016/j.critrevonc.2007.07.00417913510
   PubMed Web of Science ®Google Scholar
• YangM, McKayD, PollardJW, LewisCE. Diverse functions of macrophages in different tumor microenvironments. Cancer Res. 2018;78(19):5492–5503. doi:10.1158/0008-5472.CAN-18-136730206177
   PubMed Web of Science ®Google Scholar
• GotoW, KashiwagiS, AsanoY, et al. Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer. BMC Cancer. 2018;18(1):1137. doi:10.1186/s12885-018-5051-930453914
   PubMed Web of Science ®Google Scholar
• GuLY, LiHZ, ChenLY, et al. Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis. Oncotarget. 2016;7(22):31926–31942. doi:10.18632/oncotarget.787626942464
   PubMedGoogle Scholar
• McMillanDC, WatsonWS, O’GormanP, PrestonT, ScottHR, McArdleCS. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer. 2001;39(2):210–213. doi:10.1207/S15327914nc392_811759282
   PubMed Web of Science ®Google Scholar
• WallaceK, LiH, BrazealJG, et al. Platelet and hemoglobin count at diagnosis are associated with survival in African American and Caucasian patients with colorectal cancer. Cancer Epidemiol. 2020;67:101746. doi:10.1016/j.canep.2020.10174632521488
   PubMed Web of Science ®Google Scholar
• HuangXZ, YangYC, ChenY, et al. Preoperative anemia or low hemoglobin predicts poor prognosis in gastric cancer patients: a meta-analysis. Dis Markers. 2019;2019:7606128. doi:10.1155/2019/760612830719182
   PubMed Web of Science ®Google Scholar
• Obon-SantacanaM, FreislingH, PeetersPH, et al. Acrylamide and glycidamide hemoglobin adduct levels and endometrial cancer risk: a nested case-control study in nonsmoking postmenopausal women from the EPIC cohort. Int J Cancer. 2016;138(5):1129–1138. doi:10.1002/ijc.2985326376083
   PubMed Web of Science ®Google Scholar
• FerroM, MusiG, MateiDV, et al. Assessment of PSIM (prostatic systemic inflammatory markers) score in predicting pathologic features at robotic radical prostatectomy in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance. Diagnostics (Basel). 2021;11(2):355.33672650
   PubMedGoogle Scholar